Oxurion Enhances Board with Nelly Souleymane's Appointment

Oxurion NV, a biopharmaceutical firm based in Leuven and listed on Euronext Brussels, announced changes in its Board of Directors. Ms. Anat Loewenstein and Ms. Nathalie Laarakker will depart, effective January 13, 2025, making way for Nelly Souleymane as an independent director. This move aligns with Oxurion's strategy to boost expertise diversity and enhance stakeholder visibility.

Nelly Souleymane, bringing 19 years of experience primarily at Bayer, offers strategic communication skills. Her background includes managing reputation and executing campaigns on agricultural science and public health topics. Her expertise is expected to bolster Oxurion's communications amid sector changes.

Nelly Souleymane's appointment will be presented at the upcoming General Shareholders' Meeting, reflecting Oxurion's dedication to governance innovation and diversity.